Autophagy as a Drug Target: Separating Flux, Target Engagement and Clinical Benefit
Autophagic flux, target engagement and clinical benefit are different measurements. Human trials and a named programme illustrate the evidence boundaries.
LongevityNext Intelligence
Longevity Therapeutics
Interventions, clinical development, and the strength and limits of the evidence.
Rapamycin and Longevity: What Animal and Human Studies Separately Establish
Animal survival, authorised disease uses and human trials support different conclusions. Null endpoints and unresolved healthy-person longevity claims remain visible.
Partial Reprogramming in Human Testing: Programme Milestones, Safety Questions, and Evidence Gaps
ER-100 has sponsor-reported first dosing, while other programmes remain at different stages. Trial entry, human-cell findings and clinical benefit are not equivalent.
Senolytics Pipeline Tracker: Human Evidence, Trial Status, and Translational Limits
Tracks human senolytic evidence, registered programs, negative translation and preclinical limits.
GLP-1 Therapies and Longevity Claims: What Human Outcomes Support—and What Remains Untested
Separates molecule-specific clinical outcomes from observational, mechanistic and direct longevity claims.